Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2016

01-04-2016 | Original Article

Rapamycin inhibited the function of lung CSCs via SOX2

Authors: Li-Xia Xie, Feng-Feng Sun, Bin-Feng He, Xiao-Feng Zhan, Juan Song, Sheng-Song Chen, Shi-Cang Yu, Xiao-Qun Ye

Published in: Tumor Biology | Issue 4/2016

Login to get access

Abstract

The presence of cancer stem cells (CSCs) is the source of occurrence, aggravation, and recurrence of lung cancer. Accordingly, targeting killing the lung CSCs has been suggested to be an effective approach for lung cancer treatment. In this study, we showed that rapamycin inhibited the mammalian target of rapamycin (mTOR) signal transduction in A549 cells and improved the sensitivity to cisplatin (DDP). The mechanisms involve inhibition of the SOX2 expression, cell proliferation, epithelial-mesenchymal transition (EMT) phenotype, and sphere formation. Interestingly, knocked down SOX2 was a similar effect with rapamycin in A549 sphere. Furthermore, we showed that ectopic expression of Sox2 in A549 cells was sufficient to render them more resistant to rapamycin treatment in vitro. These data suggested that rapamycin inhibited the function of lung CSCs via SOX2. It will be of great interest to further explore the therapeutic strategies of lung cancer.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41.CrossRefPubMed
3.
Chen DQ, Huang JY, Feng B, Pan BZ, De W, Wang R, et al. Histone deacetylase 1/sp1/microrna-200b signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinoma. PLoS One. 2014;9:e109578.CrossRefPubMedPubMedCentral
4.
Ye XQ, Li Q, Wang GH, Sun FF, Huang GJ, Bian XW, et al. Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. Int J Cancer J Int Cancer. 2011;129:820–31.CrossRef
5.
Bergamaschi A, Madak-Erdogan Z, Kim YJ, Choi YL, Lu H, Katzenellenbogen BS. The forkhead transcription factor foxm1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells. Breast Cancer Res BCR. 2014;16:436.CrossRefPubMed
6.
Chai S, Tong M, Ng KY, Kwan PS, Chan YP, Fung TM, et al. Regulatory role of mir-142-3p on the functional hepatic cancer stem cell marker cd133. Oncotarget. 2014;5:5725–35.CrossRefPubMedPubMedCentral
7.
Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755–68.CrossRefPubMed
8.
Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, et al. The role of pten/akt/pi3k signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A. 2009;106:268–73.CrossRefPubMed
9.
Kornakiewicz A, Solarek W, Bielecka ZF, Lian F, Szczylik C, Czarnecka AM. Mammalian target of rapamycin inhibitors resistance mechanisms in clear cell renal cell carcinoma. Curr Signal Transduct Ther. 2014;8:210–8.CrossRefPubMed
10.
11.
Marinov M, Fischer B, Arcaro A. Targeting mtor signaling in lung cancer. Crit Rev Oncol Hematol. 2007;63:172–82.CrossRefPubMed
12.
Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, et al. Activation of the pten/mtor/stat3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A. 2007;104:16158–63.CrossRefPubMedPubMedCentral
13.
Fang DD, Zhang CC, Gu Y, Jani JP, Cao J, Tsaparikos K, et al. Antitumor efficacy of the dual pi3k/mtor inhibitor pf-04691502 in a human xenograft tumor model derived from colorectal cancer stem cells harboring a mutation. PLoS One. 2013;8:e67258.CrossRefPubMedPubMedCentral
14.
Kahn J, Hayman TJ, Jamal M, Rath BH, Kramp T, Camphausen K, et al. The mtorc1/mtorc2 inhibitor azd2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neuro-Oncology. 2014;16:29–37.CrossRefPubMed
15.
Dong P, Konno Y, Watari H, Hosaka M, Noguchi M, Sakuragi N. The impact of microrna-mediated pi3k/akt signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer. J Transl Med. 2014;12:231.CrossRefPubMedPubMedCentral
16.
Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. Sox2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41:1238–42.CrossRefPubMedPubMedCentral
17.
Sun FF, Hu YH, Xiong LP, Tu XY, Zhao JH, Chen SS, et al. Enhanced expression of stem cell markers and drug resistance in sphere-forming non-small cell lung cancer cells. Int J Clin Exp Pathol. 2015;8:6287–300.PubMedPubMedCentral
18.
Yin S, Wang P, Deng W, Zheng H, Hu L, Hurst LD, et al. Dosage compensation on the active x chromosome minimizes transcriptional noise of x-linked genes in mammals. Genome Biol. 2009;10:R74.CrossRefPubMedPubMedCentral
19.
Matsubara S, Ding Q, Miyazaki Y, Kuwahata T, Tsukasa K, Takao S. Mtor plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions. Sci Rep. 2013;3:3230.CrossRefPubMedPubMedCentral
20.
21.
Gangemi R, Paleari L, Orengo AM, Cesario A, Chessa L, Ferrini S, et al. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr Med Chem. 2009;16:1688–703.CrossRefPubMed
22.
23.
Chan CT, Pang YL, Deng W, Babu IR, Dyavaiah M, Begley TJ, et al. Reprogramming of trna modifications controls the oxidative stress response by codon-biased translation of proteins. Nat Commun. 2012;3:937.CrossRefPubMedPubMedCentral
24.
Xiao Z, Sperl B, Ullrich A, Knyazev P. Metformin and salinomycin as the best combination for the eradication of nsclc monolayer cells and their alveospheres (cancer stem cells) irrespective of egfr, kras, eml4/alk and lkb1 status. Oncotarget. 2014;5:12877–90.CrossRefPubMedPubMedCentral
25.
Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, et al. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 2011;141:1728–37.CrossRefPubMedPubMedCentral
26.
Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology. 2009;137:1102–13.CrossRefPubMed
27.
Gulhati P, Cai Q, Li J, Liu J, Rychahou PG, Qiu S, et al. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15:7207–16.CrossRef
28.
Yin S, Yang J, Lin B, Deng W, Zhang Y, Yi X, et al. Exome sequencing identifies frequent mutation of mll2 in non-small cell lung carcinoma from chinese patients. Sci Rep. 2014;4:6036.CrossRefPubMedPubMedCentral
29.
Dean M. Abc transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia. 2009;14:3–9.CrossRefPubMed
30.
Moitra K, Lou H, Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther. 2011;89:491–502.CrossRefPubMed
31.
Elliott A, Adams J, Al-Hajj M. The abcs of cancer stem cell drug resistance. IDrugs Investig Drugs J. 2010;13:632–5.
32.
Deng WJ, Nie S, Dai J, Wu JR, Zeng R. Proteome, phosphoproteome, and hydroxyproteome of liver mitochondria in diabetic rats at early pathogenic stages. Mol Cell Proteomics MCP. 2010;9:100–16.CrossRefPubMed
33.
Yin S, Deng W, Zheng H, Zhang Z, Hu L, Kong X. Evidence that the nonsense-mediated mrna decay pathway participates in x chromosome dosage compensation in mammals. Biochem Biophys Res Commun. 2009;383:378–82.CrossRefPubMed
34.
Yin S, Deng W, Hu L, Kong X. The impact of nucleosome positioning on the organization of replication origins in eukaryotes. Biochem Biophys Res Commun. 2009;385:363–8.CrossRefPubMed
35.
Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C. Salinomycin overcomes abc transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like kg-1a cells. Biochem Biophys Res Commun. 2010;394:1098–104.CrossRefPubMed
36.
Yang C, Zhang Y, Zhang Y, Zhang Z, Peng J, Li Z, Han L, You Q, Chen X, Rao X, Zhu Y, Liao Z. Downregulation of cancer stem cell properties via mtor signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma. Int J Oncol. 2015.
37.
Engelman JA. Targeting pi3k signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–62.CrossRefPubMed
38.
Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase b: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J. 1999;344(Pt 2):427–31.CrossRefPubMedPubMedCentral
39.
Zou M, Hu C, You Q, Zhang A, Wang X, Guo Q. Oroxylin a induces autophagy in human malignant glioma cells via the mtor-stat3-notch signaling pathway. Mol Carcinog. 2014.
40.
Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 2011;8:486–98.CrossRefPubMedPubMedCentral
41.
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.CrossRefPubMed
42.
Chan CT, Deng W, Li F, DeMott MS, Babu IR, Begley TJ, et al. Highly predictive reprogramming of trna modifications is linked to selective expression of codon-biased genes. Chem Res Toxicol. 2015;28:978–88.CrossRefPubMedPubMedCentral
43.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15.CrossRefPubMedPubMedCentral
44.
Pirozzi G, Tirino V, Camerlingo R, Franco R, La Rocca A, Liguori E, et al. Epithelial to mesenchymal transition by tgfbeta-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS One. 2011;6:e21548.CrossRefPubMedPubMedCentral
45.
Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating abc transporters. Cell Death Dis. 2011;2:e179.CrossRefPubMedPubMedCentral
46.
Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, et al. Sox2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. 2014;511:246–50.CrossRefPubMed
47.
Hagerstrand D, He X, Bradic Lindh M, Hoefs S, Hesselager G, Ostman A, et al. Identification of a sox2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile. Neuro-Oncology. 2011;13:1178–91.CrossRefPubMedPubMedCentral
48.
Yang N, Hui L, Wang Y, Yang H, Jiang X. Overexpression of sox2 promotes migration, invasion, and epithelial-mesenchymal transition through the wnt/beta-catenin pathway in laryngeal cancer hep-2 cells. Tumour Biol J Int Soc Oncodevelop Biol Med. 2014;35:7965–73.CrossRef
Metadata
Title
Rapamycin inhibited the function of lung CSCs via SOX2
Authors
Li-Xia Xie
Feng-Feng Sun
Bin-Feng He
Xiao-Feng Zhan
Juan Song
Sheng-Song Chen
Shi-Cang Yu
Xiao-Qun Ye
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4341-y

Other articles of this Issue 4/2016

Tumor Biology 4/2016 Go to the issue

Original Article

Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics

Original Article

Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study

Original Article

Esculetin, a natural coumarin compound, evokes Ca2+ movement and activation of Ca2+-associated mitochondrial apoptotic pathways that involved cell cycle arrest in ZR-75-1 human breast cancer cells

Original Article

Hotspot TERT promoter mutations are rare events in testicular germ cell tumors

Original Article

Mitotic arrest deficient-like 1 is correlated with poor prognosis in small-cell lung cancer after surgical resection

Original Article

RRAD inhibits aerobic glycolysis, invasion, and migration and is associated with poor prognosis in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits